GPhA shows support for National Prescription Drug Take-Back Day
WASHINGTON — Saturday is the Drug Enforcement Administration’s National Prescription Drug Take-Back Day, and the country’s largest lobbying group representing the generic drug industry is expressing its support.
The Generic Pharmaceutical Association said its support for the program was part of a commitment to work with such stakeholders as doctors, parents, law enforcement, lawmakers and industry to try and stop diversion of prescription drugs in the United States. According to the 2009 National Study of Drug Use and Health, the problem of prescription drug abuse primarily stems from drugs that are legally prescribed and available in the home.
"With recent studies showing that as many as 70% of people abusing prescription drugs were doing so with products they obtained from a friend or relative, it is imperative that we act now to ensure that these medications are not falling into the wrong hands," GPhA president and CEO Ralph Neas said. "The DEA’s National Prescription Take-Back Day is an excellent example of the multi-stakeholder collaboration that is needed to tackle this problem."
The DEA program will involve nearly 4,000 state and local law enforcement agencies and will collect expired, unused and unwanted prescription drugs. The first two National Prescription Take Back Days collected more than 309 tons of pills, according to the GPhA.
Daily rate for Redbox DVD rentals to increase
BELLEVUE, Wash. — Shoppers that take advantage of Redbox rentals should expect to see a change in price.
Redbox’s parent company Coinstar on Thursday said that the daily rate for standard DVD rentals will increase 20 cents to $1.20. Prices for Blu-ray format movie rentals and for video game rentals, however, will not change and continue to be $1.50 and $2, respectively.
"We remain committed to providing redbox consumers access to the latest movies at an incredible value," Coinstar CEO Paul Davis said. "This marks the first price increase for a Redbox standard definition DVD rental in eight years. The change is primarily due to the increase in operating expenses, including the recent increase in debit card interchange fees as a result of the Durbin Amendment."
FDA approves supplemental new drug application for Abbott’s Lupron Depot-PED
ABBOTT PARK, Ill. — The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.
Abbott said the FDA approved its sNDA for Lupron Depot-PED (leuprolide acetate) for depot suspension, saying the one-month formulation was the first product in its class to include long-term data in its label for the treatment of central precocious puberty, or CPP, which causes children to enter puberty too soon. The prescribing information now includes 19 years of data, including prespecified outcome results on puberty, height and reproductive function.
Abbott’s application included data from an open-label study that enrolled 55 patients between the ages of 5 years and 9 years in a treatment phase. Patients were assessed for signs and symptoms of puberty, a hormone called LH and reproductive function. During treatment, Abbott said, puberty was suppressed and normalized growth rates were achieved.
"Guiding a child through puberty can be a challenge for any parent, but when things go awry in the body and this process happens too soon, it can be worrisome for everyone," Abbott SVP global pharmaceutical research and development John Leonard said. "This study provides patients and physicians with important information to better understand Lupron Depot-PED for one-month administration and its long-term impact, particularly on reproductive function and normalized adult height."